The biotech sector navigates complex regulatory and financial dynamics. The Supreme Court upheld cuts to $783 million in NIH research funds linked to diversity, equity, and inclusion efforts, a controversial decision impacting research funding. Sarepta Therapeutics announced refinancing of approximately $700 million of convertible senior notes, strengthening its financial structure. QuidelOrtho completed a $3.4 billion debt refinancing to improve liquidity. Additionally, new bipartisan Congressional BIOTech Caucus launched to sustain U.S. leadership in emerging biotechnology and biosecurity.